Vistagen Therapeutics, Inc. 8-K

What Happened
Vistagen Therapeutics, Inc. (VTGN) filed an 8-K (Item 5.02) announcing that two board members — Margaret FitzPatrick and Dr. Joanne Curley — have notified the company they will not stand for re-election at the company’s 2026 Annual Meeting of Stockholders. Ms. FitzPatrick informed the company on June 16, 2026, and Dr. Curley on June 17, 2026. Each will continue to serve as a director until the end of her term at the 2026 Annual Meeting. The report was signed by President and CEO Shawn K. Singh on June 17, 2026.

Key Details

• Filing type: Form 8-K (Item 5.02 — Departure of Directors or Certain Officers) filed June 17, 2026.
• Directors not standing for re-election: Margaret FitzPatrick (notice dated June 16, 2026) and Dr. Joanne Curley (notice dated June 17, 2026).
• Effective timing: Both will remain directors until their terms end at the 2026 Annual Meeting.
• The 8-K provides notice only; it does not identify replacements or changes to board committees.

Why It Matters
Board departures change the makeup of the company’s governance team and will be reflected on the ballot at the upcoming annual meeting. While this 8-K merely notifies investors of the directors’ decisions not to seek re-election, investors should watch for subsequent filings (proxy statement or additional 8-Ks) disclosing any new nominees, committee reassignments, or other board changes that could affect corporate oversight.